Holen Sie sich die Stockscreener-App
0.00
100.00%
-3.87
Handel nachbörslich:
3.87
3.87
+
Schlusskurs vom Vortag:
$3.87
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$25.68M
Einnahmen:
$5.21M
Nettoeinkommen (Verlust:
$-26.35M
KGV:
0.00
EPS:
-32.0862
Netto-Cashflow:
$-20.84M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$8.00
Plus Therapeutics Inc Stock (PSTV) Company Profile
Firmenname
Plus Therapeutics Inc
Sektor
Branche
Telefon
737.255.7194
Adresse
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.00 | 25.68M | 5.21M | -26.35M | -20.84M | -32.09 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-03 | Eingeleitet | Lake Street | Buy |
| 2025-09-03 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2025-03-17 | Eingeleitet | D. Boral Capital | Buy |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-16 | Eingeleitet | Maxim Group | Buy |
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
Plus Therapeutics (CNSY) 10K Form and Latest SEC Filings 2026 - MarketBeat
Plus Therapeutics (CNSY) Stock Forecast and Price Target 2026 - MarketBeat
Cerenome Doubles Down on Hines’ Levit Green Campus - The Real Deal
Plus Therapeutics (CNSY) Stock Price, News & Analysis - MarketBeat
Radiation therapy co. Cerenome plans major expansion at Hines' Levit Green campus - The Business Journals
PLUS (PSTV) Range: Trades in a Narrow Directional Range at $3.87 in the Latest Session; Market Levels: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionIndex Put Call - Vinanet
Plus Therapeutics (CNSY) Stock Trends and Sentiment 2026 - MarketBeat
Plus Therapeutics (CNSY) Q2 Earnings Miss Highlight Challenges A - GuruFocus
Plus Therapeutics Stock Price Forecast. Should You Buy PSTV? - StockInvest.us
Plus Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cerenome Reports $9.0 Million Second-Quarter 2026 Net Loss - Quiver Quantitative
Cerenome Reports Second Quarter 2026 Financial Results and Business Update - The Manila Times
Plus Therapeutics (CNSY) Financials 2026Income Statement and Balance Sheet - MarketBeat
Plus Therapeutics (CNSY) Earnings Date and Reports 2026 - MarketBeat
PSTV Stock On Track For Best Week Since September — Here’s What Is Driving The Rally - Stocktwits
Plus Therapeutics (CNSY) Stock Chart and Price History 2026 - MarketBeat
Technical Analysis of Cerenome, Inc. (NASDAQ:CNSY) - TradingView
Plus Therapeutics Inc expected to post a loss of 91 cents a shareEarnings Preview - TradingView
Plus Therapeutics Inc (PSTV) Stock News Today - TradingKey
Plus Therapeutics Inc (PSTV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cerenome, Inc.: Target Price Consensus and Analysts Recommendations | CNSY | US72941H8060 - marketscreener.com
CNSY Forecast — Price Target — Prediction for 2027 - TradingView
Cerenome, Inc. (CNSY) rebrands from Plus Therapeutics with new ticker - Stock Titan
Plus Therapeutics amends bylaws to reflect corporate name change to Cerenome - Bitget
Plus Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Plus Therapeutics Rebrands with Launch of Cerenome - Contract Pharma
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Plus Therapeutics rebrands as Cerenome - AuntMinnie
Plus Therapeutics, Inc. will Change its Ticker to CNSY from PSTV - marketscreener.com
Plus Therapeutics, Inc. will Change its Name to Cerenome - marketscreener.com
Plus Therapeutics Inc (PSTV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Plus Therapeutics Announces Scientific Presentations and - GlobeNewswire
PSTV|Plus Therapeutics Inc|Price:3.770|Chg%:-0.060 - TradingKey
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference - Yahoo Finance
Plus Therapeutics to Present New Research at SNO/ASCO Conference - Intellectia AI
Plus Therapeutics Inc (PSTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Plus Therapeutics Inc (PSTV) Cash Flow - TradingKey
Plus Therapeutics Inc (PSTV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Plus Therapeutics Inc (PSTV) Income Statement - TradingKey
Plus Therapeutics Inc (PSTV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PLUS THERAPEUTICS Inc. (PSTV) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Plus Therapeutics Inc (PSTV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Plus Therapeutics Inc. R (XMP1.DU) stock price, news, quote and history - Yahoo Finance UK
Plus Therapeutics, Inc. (PSTV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Plus Therapeutics secures regional coverage for... - Pluang
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - The Manila Times
CNSide Diagnostics signs coverage deal with Medical Mutual - Investing.com
CNSide Diagnostics signs coverage deal with Medical Mutual By Investing.com - Investing.com Canada
Finanzdaten der Plus Therapeutics Inc-Aktie (PSTV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):